Knowledge, Attitudes, and Likelihood of Pre-Exposure Prophylaxis (PrEP) Use Among US Women at Risk of Acquiring HIV
Knowledge, Attitudes, and Likelihood of Pre-Exposure Prophylaxis (PrEP) Use Among US Women at Risk of Acquiring HIV
复制标题
DOI：
10.1089/apc.2014.0142
复制
发表时间：
2015-02-01
影响因子：
4.9
通讯作者：
Charles, Vignetta
中科院分区：
文献类型：
--
作者：
Auerbach, Judith D.;Kinsky, Suzanne;Charles, Vignetta
尽管美国食品和药物管理局 (FDA) 于 2012 年 7 月批准口服特鲁瓦达用于针对有 HIV 感染风险的女性进行暴露前预防 (PrEP)，并且美国疾病控制与预防中心 (CDC) 于 2014 年 5 月发布了临床医生向“处于 HIV 感染高风险”的女性提供 PrEP 的指南，但仍然没有关于美国女性疗效的临床试验数据，并且缺乏关于知识、态度和使用该药物的可能性的研究。其中包括 PrEP。 2013 年 7 月至 9 月期间，我们对美国六个城市的 144 名高危女性进行了一项定性焦点小组 (FG) 研究，其中包括美国南部地区，那里的女性艾滋病毒感染最为普遍。 FG 问题引发了对 PrEP 的认识、对给药和使用的态度以及使用的障碍和促进因素。女性对在研究之前没有听说过 PrEP 表示愤怒，但一旦了解后，大多数人发现它很有吸引力。 PrEP 被视为对安全套的额外保护，而不是替代保护，参与者提出了几种传播策略，以满足妇女的不同需求。 PrEP 普及的主要障碍包括对医疗系统的不信任、耻辱和费用。研究结果表明，美国女性将 PrEP 视为一种重要的预防选择，假设副作用和消费者成本极小，药物疗效合理，并且 PrEP 由值得信赖的提供商在值得信赖的场所提供。
Although the Food and Drug Administration (FDA) approved oral Truvada for pre-exposure prophylaxis (PrEP) for women at risk of HIV infection in the US in July 2012, and the Centers for Disease Control and Prevention (CDC) issued guidance for clinicians to provide PrEP to women "at substantial risk of HIV acquisition" in May 2014, there remain no clinical trial data on efficacy among US women, and there is a dearth of research on knowledge, attitudes, and likelihood of use of PrEP among them. We conducted a qualitative focus group (FG) study with 144 at-risk women in six US cities between July and September 2013, including locations in the Southern US, where HIV infections among women are most prevalent. FG questions elicited awareness of PrEP, attitudes about administration and uptake, and barriers to and facilitators of use. Women expressed anger at the fact that they had not heard of PrEP prior to the study, but once informed most found it attractive. PrEP was seen as additional, not substitute protection to condoms, and participants suggested several dissemination strategies to meet the diverse needs of women. Key barriers to PrEP uptake included distrust of the medical system, stigma, and cost. Findings suggest that US women view PrEP as an important prevention option, assuming side effects and the cost to the consumer are minimal, the efficacy of the drug is reasonable, and PrEP is delivered by trusted providers in trusted venues.